Medical Heart Articles & Analysis
24 news found
The HFSA Optimal Medical Therapy in Heart Failure (OMT-HF) program can help your patients achieve their best outcomes. An estimated 6.5 million Americans have heart failure (HF). This year alone another 960,000 will likely be diagnosed with this condition. ...
$5.5M financing led by Taiho Ventures LLC, with participation of existing investors, including the Series Seed lead, Kizoo Technology Capital GmbH Fresh capital to be employed to get cellvie Series A ready by accelerating the development of the company's technology platform, strengthening the team, and advancing the mitochondria's GMP manufacturing cellvie Inc., a leader in Therapeutic ...
Richardson has over 30 years of experience in the medical device industry, and an extensive record of successfully taking medtech companies from startup to commercialization to acquisition. Most recently, he was President and CEO of Keystone Heart, a structural heart medical device company, and creator of the first Cerebral ...
BySafeHeal
“Nasdaq’s long tradition of listing category-defining medical technology companies aligns well with Daxor’s innovative blood volume technology portfolio,” commented Michael Feldschuh, CEO and President of Daxor. ...
JenaValve is backed by Bain Capital Life Sciences and Cormorant Asset Management as well as European and Asian investors, including Andera Partners, Gimv (Euronext: GIMB), Legend Capital, NeoMed Management, RMM, Valiance Life Sciences, VI Partners, and Peijia Medical Limited (HKEX: 9996). About Peijia Medical Peijia Medical was founded in 2012, ...
The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. ...
Blood volume analysis is an important measure of health, surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. ...
Blood volume analysis is an important measure of health, surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. ...
We are actively developing hardware and software solutions embodying these patented concepts—with the support of the National Institutes of Health—to help all clinicians achieve the kind of improved outcomes demonstrated by experts using blood-volume-guided treatment for conditions such as heart failure and trauma.” “This patent award is a significant ...
These data from two separate studies were presented at the American Heart Association (AHA) Scientific Sessions virtual meeting from November 13-15, 2021. ...
About Daxor Corporation Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations). We developed and market the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by ...
The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. ...
These data were published in the ESC Heart Failure Journal. In the previously published, first meta-analysis,1 which was focused on patient echocardiographic data, the authors concluded “This comprehensive meta-analysis of individual patient data has shown that Carillon device provides statistically significant and clinically meaningful benefits on MR severity, LA and LV ...
About Ametus Group Headquartered in the heart of Medical Alley, the epicenter of medical device companies, in St. Paul, Minnesota, The Ametus Group drives new revenue generation by providing master or regional sales distribution capabilities focused on clinically novel medical device products that represent specific ...
BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter Ventricular Restoration (TCVR), today announced that heart failure specialist Jerry Estep, MD, of the Cleveland Clinic has been appointed co-principal investigator of the pivotal ALIVE Trial studying LIVE Therapy using ...
V-Wave Ltd., a privately held medical device company developing novel implantable devices for the treatment of Heart Failure (HF), today announced that its Ventura™ Interatrial Shunt System received CE Mark and is now approved to be marketed for use in the European Union. “More than 26 million people suffer from chronic ...
He joins co-principal investigators Stefan Anker, MD, of the Berlin-Brandenburger Center for Regenerative Therapy (BCRT) and Volkmar Falk, MD, Medical Director and Director of the Department of Cardiothoracic Vascular Surgery at the German Heart Center, Berlin. “I am enthusiastic about joining the investigation of this new approach providing a much-needed ...
For patients where heart failure has progressed beyond the ability of medications and pacemakers to manage symptoms, minimally invasive percutaneous device therapy with the AccuCinch System may provide an effective treatment option. ...
This represents the next step in achieving our ultimate goal of providing remote cardiovascular care to patients suffering a heart attack or stroke who do not currently have access to potentially life-saving coronary and stroke interventions,” said Dr. ...
The Carillon System is a right heart transcatheter mitral valve repair (TMVr) device designed to treat the primary cause of FMR in patients with MR grades 2+, 3+ and 4+. “We know that mitral regurgitation in the context of heart failure is strongly associated with increased morbidity and mortality,” commented Prof. ...